Recent U.S. Food and Drug Administration Labeling Changes for Hydroxyethyl Starch Products Due to Concerns about Mortality, Kidney Injury, and Excess Bleeding

Anesthesiology. 2022 May 1;136(5):868-870. doi: 10.1097/ALN.0000000000004164.

Authors

Laurence Landow¹, Shaokui Wei, Linye Song, Ravi Goud, Katherine Cooper

Affiliation

¹ U.S. Food and Drug Administration, Silver Spring, Maryland (L.L.). laurence.landow@fda.hhs.gov.

PMID: 35258516
DOI: 10.1097/ALN.0000000000004164

No abstract available

Publication types

Letter

MeSH terms

Acute Kidney Injury* / chemically induced
Acute Kidney Injury* / drug therapy
Fluid Therapy
Humans
Hydroxyethyl Starch Derivatives* / adverse effects
Kidney
Plasma Substitutes / therapeutic use
United States
United States Food and Drug Administration

Substances

Hydroxyethyl Starch Derivatives
Plasma Substitutes